黄芪作为炎症性肠病药物候选物：临床前证据。
Astragalus membranaceus as a Drug Candidate for Inflammatory Bowel Disease: The Preclinical Evidence.
发表日期：2023 Aug 03
作者：
Min Hou, Yufang Leng, Yajing Shi, Zhiguo Tan, Xiangzhen Min
来源：
ANTIOXIDANTS & REDOX SIGNALING
摘要：
炎症性肠病（IBD）是一组慢性炎症性疾病，包括克罗恩病（CD）和溃疡性结肠炎（UC）。目前，对于IBD还没有成功的治疗方法。因此，开发新的治疗药物对于IBD的预防和治疗至关重要。黄芪（Astragalus membranaceus， AMS）是一种传统中药，源于黄芪的根部。现代药理学研究表明，AMS及其成分具有多种生物活性，如抗炎、抗氧化、免疫调节、抗癌、降脂、降血糖、保护肝脏、祛痰和利尿等作用。AMS及其活性成分据报道在治疗IBD方面有效，被认为是治疗IBD的有希望的候选药物。这些潜在机制与抗炎、抗氧化、免疫调节、肠道上皮修复、肠道微生物群稳态以及改善能量代谢有关。本综述总结了AMS及其活性成分在临床前研究中在IBD治疗中的疗效和相关机制。
Inflammatory bowel disease (IBD) is a group of chronic inflammatory disorders that include Crohn's disease (CD) and ulcerative colitis (UC). Today, IBD has no successful treatment. As a result, it is of paramount importance to develop novel therapeutic agents for IBD prevention and treatment. Astragalus membranaceus (AMS) is a traditional Chinese medicine found in the AMS root. Modern pharmacological studies indicate that AMS and its constituents exhibit multiple bioactivities, such as anti-inflammatory, anti-oxidant, immune regulatory, anticancer, hypolipidemic, hypoglycemic, hepatoprotective, expectorant, and diuretic effects. AMS and its active constituents, which have been reported to be effective in IBD treatment, are believed to be viable candidate drugs for IBD treatment. These underlying mechanisms are associated with anti-inflammation, anti-oxidation, immunomodulation, intestinal epithelial repair, gut microbiota homeostasis, and improved energy metabolism. In this review, we summarize the efficacy and underlying mechanisms involved in IBD treatment with AMS and its active constituents in preclinical studies.